NASDAQ:CLSN - Celsion Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.00
  • Forecasted Upside: 183.69 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.41
▼ -0.13 (-8.44%)
1 month | 3 months | 12 months
Get New Celsion Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLSN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLSN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$4.00
▲ +183.69% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Celsion in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 183.69% upside from the last price of $1.41.

Hold

The current consensus among 2 investment analysts is to hold stock in Celsion. This rating has held steady since June 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/21/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/15/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/16/2020OppenheimerDowngradeOutperform ➝ Market PerformMedium
i
7/13/2020Dawson JamesDowngradeBuy ➝ NeutralMedium
i
Rating by Jason Kolbert at Dawson James
6/24/2020Dawson JamesReiterated RatingBuy$4.00Low
i
7/25/2019Brookline Capital ManagementReiterated RatingBuyMedium
i
Rating by K. Raja at Brookline Capital Management
3/19/2019OppenheimerReiterated RatingBuyLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/20/2018Brookline Capital ManagementReiterated RatingBuyMedium
i
Rating by K. Raja at Brookline Capital Management
11/15/2018OppenheimerSet Price TargetBuy$9.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/21/2017OppenheimerInitiated CoverageOutperform$9.00N/A
i
10/4/2017Maxim GroupUpgradeHold ➝ Buy$7.00High
i
Rating by Jason McCarthy at Maxim Group
8/15/2017Maxim GroupReiterated RatingHoldMedium
i
Rating by Jason McCarthy at Maxim Group
8/7/2017Maxim GroupReiterated RatingHoldLow
i
Rating by Jason McCarthy at Maxim Group
6/1/2017Maxim GroupReiterated RatingHoldLow
i
Rating by Jason McCarthy at Maxim Group
4/20/2017Maxim GroupReiterated RatingHoldMedium
i
Rating by Jason McCarthy at Maxim Group
4/10/2017Rodman & RenshawReiterated RatingBuy$21.00High
i
4/10/2017HC WainwrightReiterated RatingBuy$21.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/16/2017Maxim GroupReiterated RatingHoldHigh
i
Rating by Jason McCarthy at Maxim Group
11/14/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/10/2016Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason McCarthy at Maxim Group
10/11/2016Maxim GroupSet Price TargetBuy$56.00N/A
i
Rating by Jason McCarthy at Maxim Group
9/15/2016Maxim GroupReiterated RatingBuy$56.00N/A
i
Rating by Jason McCarthy at Maxim Group
8/16/2016Maxim GroupReiterated RatingBuy$56.00N/A
i
Rating by Jason McCarthy at Maxim Group
7/22/2016Maxim GroupReiterated RatingBuy$56.00N/A
i
Rating by Jason McCarthy at Maxim Group
7/12/2016HC WainwrightReiterated RatingBuy$42.00N/A
i
Rating by Mark Breidenbach at HC Wainwright
7/11/2016Maxim GroupReiterated RatingBuy$126.00N/A
i
Rating by Jason McCarthy at Maxim Group
(Data available from 6/14/2016 forward)
Celsion logo
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Read More

Today's Range

Now: $1.41
$1.38
$1.52

50 Day Range

MA: $1.18
$0.98
$1.54

52 Week Range

Now: $1.41
$0.43
$6.50

Volume

5,648,308 shs

Average Volume

11,997,908 shs

Market Capitalization

$122.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Celsion?

The following Wall Street research analysts have issued reports on Celsion in the last twelve months: Dawson James, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for CLSN.

What is the current price target for Celsion?

1 Wall Street analysts have set twelve-month price targets for Celsion in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 183.7%. Dawson James has the highest price target set, predicting CLSN will reach $4.00 in the next twelve months. Dawson James has the lowest price target set, forecasting a price of $4.00 for Celsion in the next year.
View the latest price targets for CLSN.

What is the current consensus analyst rating for Celsion?

Celsion currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CLSN, but not buy more shares or sell existing shares.
View the latest ratings for CLSN.

What other companies compete with Celsion?

How do I contact Celsion's investor relations team?

Celsion's physical mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company's listed phone number is (609) 896-9100 and its investor relations email address is [email protected] The official website for Celsion is www.celsion.com.